Estrone sulfatase activity in patients with advanced ovarian cancer

Justin C. Chura, Charles H. Blomquist, Hyung S. Ryu, Peter A Argenta

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: We sought to identify whether the sulfatase pathway was present in ovarian cancer specimens and then to determine whether a clinical correlation existed between sulfatase activity and survival. Materials and methods: Enzymatic activity was assessed in advanced ovarian cancer specimens via thin layer chromatography and standardized against total protein. All enzyme activities are reported in pmol/mg protein/30 min. Kaplan Meier curves of progression-free and overall survival were constructed to compare outcomes between patients with low sulfatase activity and high sulfatase activity. Median survival rates were compared using the log-rank test for survival curves. Differences in proportions between patients with low sulfatase activity versus high sulfatase activity were compared with the z-test or chi-square analysis as appropriate. Results: 37 specimens from patients with advanced stage ovarian cancer were analyzed. Enzymatic activity was detected in all specimens except one. Median progression-free survival was 23.5 months for patients with low sulfatase activity compared to 6.9 months for patients with high sulfatase activity (p = 0.008). Median overall survival favored the low sulfatase group (50.8 vs. 30.6 months respectively), though statistical difference was not detected (p = 0.16). No other difference in clinical characteristics between patients with high or low sulfatase activity was detected. Conclusions: Sulfatase activity is widely present in ovarian cancer specimens. Increased sulfatase activity is associated with worse progression-free survival in patients with advanced stage ovarian cancer. The sulfatase pathway is a potential therapeutic target in the treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)205-209
Number of pages5
JournalGynecologic oncology
Volume112
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Sulfatases
Ovarian Neoplasms
Disease-Free Survival
estrone sulfatase
Survival
Chi-Square Distribution
Thin Layer Chromatography

Keywords

  • Carcinoma
  • Endocrine therapy
  • Estrogen
  • Estrone sulfate
  • Ovarian cancer
  • Steroid converting enzymes

Cite this

Estrone sulfatase activity in patients with advanced ovarian cancer. / Chura, Justin C.; Blomquist, Charles H.; Ryu, Hyung S.; Argenta, Peter A.

In: Gynecologic oncology, Vol. 112, No. 1, 01.01.2009, p. 205-209.

Research output: Contribution to journalArticle

Chura, Justin C. ; Blomquist, Charles H. ; Ryu, Hyung S. ; Argenta, Peter A. / Estrone sulfatase activity in patients with advanced ovarian cancer. In: Gynecologic oncology. 2009 ; Vol. 112, No. 1. pp. 205-209.
@article{5b1acff62d7c4a7e955dcfb05a669379,
title = "Estrone sulfatase activity in patients with advanced ovarian cancer",
abstract = "Introduction: We sought to identify whether the sulfatase pathway was present in ovarian cancer specimens and then to determine whether a clinical correlation existed between sulfatase activity and survival. Materials and methods: Enzymatic activity was assessed in advanced ovarian cancer specimens via thin layer chromatography and standardized against total protein. All enzyme activities are reported in pmol/mg protein/30 min. Kaplan Meier curves of progression-free and overall survival were constructed to compare outcomes between patients with low sulfatase activity and high sulfatase activity. Median survival rates were compared using the log-rank test for survival curves. Differences in proportions between patients with low sulfatase activity versus high sulfatase activity were compared with the z-test or chi-square analysis as appropriate. Results: 37 specimens from patients with advanced stage ovarian cancer were analyzed. Enzymatic activity was detected in all specimens except one. Median progression-free survival was 23.5 months for patients with low sulfatase activity compared to 6.9 months for patients with high sulfatase activity (p = 0.008). Median overall survival favored the low sulfatase group (50.8 vs. 30.6 months respectively), though statistical difference was not detected (p = 0.16). No other difference in clinical characteristics between patients with high or low sulfatase activity was detected. Conclusions: Sulfatase activity is widely present in ovarian cancer specimens. Increased sulfatase activity is associated with worse progression-free survival in patients with advanced stage ovarian cancer. The sulfatase pathway is a potential therapeutic target in the treatment of ovarian cancer.",
keywords = "Carcinoma, Endocrine therapy, Estrogen, Estrone sulfate, Ovarian cancer, Steroid converting enzymes",
author = "Chura, {Justin C.} and Blomquist, {Charles H.} and Ryu, {Hyung S.} and Argenta, {Peter A}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2008.08.037",
language = "English (US)",
volume = "112",
pages = "205--209",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Estrone sulfatase activity in patients with advanced ovarian cancer

AU - Chura, Justin C.

AU - Blomquist, Charles H.

AU - Ryu, Hyung S.

AU - Argenta, Peter A

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Introduction: We sought to identify whether the sulfatase pathway was present in ovarian cancer specimens and then to determine whether a clinical correlation existed between sulfatase activity and survival. Materials and methods: Enzymatic activity was assessed in advanced ovarian cancer specimens via thin layer chromatography and standardized against total protein. All enzyme activities are reported in pmol/mg protein/30 min. Kaplan Meier curves of progression-free and overall survival were constructed to compare outcomes between patients with low sulfatase activity and high sulfatase activity. Median survival rates were compared using the log-rank test for survival curves. Differences in proportions between patients with low sulfatase activity versus high sulfatase activity were compared with the z-test or chi-square analysis as appropriate. Results: 37 specimens from patients with advanced stage ovarian cancer were analyzed. Enzymatic activity was detected in all specimens except one. Median progression-free survival was 23.5 months for patients with low sulfatase activity compared to 6.9 months for patients with high sulfatase activity (p = 0.008). Median overall survival favored the low sulfatase group (50.8 vs. 30.6 months respectively), though statistical difference was not detected (p = 0.16). No other difference in clinical characteristics between patients with high or low sulfatase activity was detected. Conclusions: Sulfatase activity is widely present in ovarian cancer specimens. Increased sulfatase activity is associated with worse progression-free survival in patients with advanced stage ovarian cancer. The sulfatase pathway is a potential therapeutic target in the treatment of ovarian cancer.

AB - Introduction: We sought to identify whether the sulfatase pathway was present in ovarian cancer specimens and then to determine whether a clinical correlation existed between sulfatase activity and survival. Materials and methods: Enzymatic activity was assessed in advanced ovarian cancer specimens via thin layer chromatography and standardized against total protein. All enzyme activities are reported in pmol/mg protein/30 min. Kaplan Meier curves of progression-free and overall survival were constructed to compare outcomes between patients with low sulfatase activity and high sulfatase activity. Median survival rates were compared using the log-rank test for survival curves. Differences in proportions between patients with low sulfatase activity versus high sulfatase activity were compared with the z-test or chi-square analysis as appropriate. Results: 37 specimens from patients with advanced stage ovarian cancer were analyzed. Enzymatic activity was detected in all specimens except one. Median progression-free survival was 23.5 months for patients with low sulfatase activity compared to 6.9 months for patients with high sulfatase activity (p = 0.008). Median overall survival favored the low sulfatase group (50.8 vs. 30.6 months respectively), though statistical difference was not detected (p = 0.16). No other difference in clinical characteristics between patients with high or low sulfatase activity was detected. Conclusions: Sulfatase activity is widely present in ovarian cancer specimens. Increased sulfatase activity is associated with worse progression-free survival in patients with advanced stage ovarian cancer. The sulfatase pathway is a potential therapeutic target in the treatment of ovarian cancer.

KW - Carcinoma

KW - Endocrine therapy

KW - Estrogen

KW - Estrone sulfate

KW - Ovarian cancer

KW - Steroid converting enzymes

UR - http://www.scopus.com/inward/record.url?scp=57649183895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649183895&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.08.037

DO - 10.1016/j.ygyno.2008.08.037

M3 - Article

C2 - 18947862

AN - SCOPUS:57649183895

VL - 112

SP - 205

EP - 209

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -